Based on updated data from the TRUST-1 trial, taletrectinib is now approved by the FDA for patients with TKI-naive ROS1+ NSCLC.
|Articles|November 1, 2007
Oncology NEWS International
- Oncology NEWS International Vol 16 No 11
- Volume 16
- Issue 11
Phase II trials planned for oral methylnaltrexone for chronic pain
Phase II trials planned for oral methylnaltrexone for chronic pain
Advertisement
COLLEGEVILLE, PennsylvaniaWyeth Pharmaceuticals and Progenics plan to initiate two 4-week phase II clinical trials to evaluate daily dosing of oral methylnaltrexone in patients with chronic, nonmalignant pain who are experiencing opioid-induced constipation (OIC). An NDA for the subcutaneous formulation has been filed with FDA for the treatment of OIC in the end-of-life setting.
Articles in this issue
almost 19 years ago
MT103, BiTE antibody, enters phase II testing for ALLalmost 19 years ago
Sides dig in as ESA policy debate heats upalmost 19 years ago
Ixempra gets ok for resistant breast canceralmost 19 years ago
ASCO adds Oncotype DX to marker guidelinealmost 19 years ago
Dr. Norton hopes to weed 'molecular' tumor gardenalmost 19 years ago
Accelerated approval for Tasignaalmost 19 years ago
Oxidative stress inducer ups survival in advanced melanomaalmost 19 years ago
FDA removes partial hold on Telcyta clinical developmentalmost 19 years ago
Should all HER2+ pts receive adjuvant trastuzumab?almost 19 years ago
R-CHOP is standard of care for advanced DLBCL patientsAdvertisement
Related to this article
Misako Nagasaka, MD, PhD, explains how subcutaneous amivantamab’s shorter administration time benefits patients and infusion centers.
Jasmine Zain, MD, emphasized the importance of good patient counseling when outlining the potential risks of secondary T-cell malignancies following CAR T-cell therapy.
Misako Nagasaka, MD, PhD, discusses PALOMA-2’s 70% 3-year survival rate compared with historical MARIPOSA data for intravenous amivantamab.
Adult T-cell lymphoma and leukemia may warrant upfront allogeneic transplant, according to Mary Jo Lechowicz, MD.
Poster presentations at SOHO 2026 may inform multiple myeloma practice across the newly diagnosed and relapsed/refractory settings.
The IND clearance for IASO208, a CD20-targeted in vivo CAR-T therapy requiring no leukapheresis or lymphodepletion, enables advancement of a phase 1b trial.
The OMNI-EGFR inhibitor BH-30643 produced a 45% objective response rate among patients with EGFR C797S–positive disease in the phase 1/2 SOLARA trial.
Advertisement
Advertisement
Trending on CancerNetwork
1
IASO208 Receives FDA IND Clearance for Relapsed/Refractory B-Cell Lymphoma
2
WCLC 2026: How Will The Small Cell Lung Cancer Paradigm Change?
3
SOHO 2026: Key Updates Across the Multiple Myeloma Continuum
4
Secondary T-Cell Malignancies: Identifying and Counseling After CAR T-Cell Therapy
5